Barault 2015.

Study characteristics
Study design	Cohort
Study setting	Setting: VU University Medical Center, Amsterdam Country: the Netherlands Dates: diagnosis between 2005 and 2011
Selection of participants	Eligible people had a histopathological diagnosis of supratentorial GBM. The GBM validation‐set consisted of tissue samples from people with newly diagnosed GBM, who had surgery and chemoradiation with follow‐up ≥ 2 years. Inclusion criteria: adults aged > 17 years; a new histopathological diagnosis of supratentorial GBM between 2005 and 2011, verified by an independent neuropathologist; no prior brain tumour treatment to exclude dedifferentiated glioma; pre‐ and postoperative MRI within 3 days of surgery; standard adjuvant therapy
Participant characteristics	Sample size: 66 (deaths: NR) Age: NR Sex: % men NR KPS: NR
Tumour characteristics	GBM: 100% First diagnosis: 100% Biopsy: 3%; subtotal resection: NR; total resection: 97% IDH1 wild‐type: NR; IDH2 wild‐type: NR
Treatment regimen	Standard adjuvant therapy consisting of radiotherapy and concomitant TMZ, followed by 6 monthly cycles of adjuvant TMZ
MGMT promoter methylation tests implemented	PSQ, methyl‐beaming
Dates and follow‐up	Timing of MGMT assessment: not explicitly reported, but presumably on material obtained during resective surgery, prior to adjuvant therapy with 30 × 2 Gy radiotherapy and concomitant TMZ, followed by 6 monthly cycles of adjuvant TMZ. Start time for follow‐up: NR; follow‐up: median NR; range NR
Notes